Collective experience in research and development of new drugs has shown that the initial safety, effectiveness, predictability, reproducibility, and clinical applicability results are directly connected with the need to establish an ideal preclinical animal model platform. Introducing human-related genes into mice to construct genetically humanized mice that can better simulate and predict the process of human disease yields a widely used experimental animal model with numerous application advantages.
Genetically engineered humanized mouse models include a wide variety of gene modification strategies, such as point mutation, small knockin, and large-fragment knockin. Among these, it is easier to prepare point mutations and small fragment knockin mice. In contrast, the preparation of large genome fragment knockin humanized mice is technically challenging.
In this webinar, experts will lead us to explore the strategies for generating humanized mice with large fragment knockin (LFKI), application areas, current technical difficulties, and breakthroughs.
